Four Potential Suitors for Onyx Pharmaceuticals, Inc. (ONXX)

Page 1 of 2

The “people familiar with the matter” are out in full force spouting off about who’s bidding for Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX), reports Reuters and The Wall Street Journal.

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)

The insiders — most likely Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)’s bankers — release the confidential information to help drive up the price. You’ll recall that Amgen, Inc. (NASDAQ:AMGN) recently made an unsolicited bid for $120 per share that Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) rejected before putting itself on the auction block. The more potential bidders, the higher Amgen has to raise its bid, assuming, of course, that Amgen, Inc. (NASDAQ:AMGN) believes what’s reported in the press.

The news flow also encourages shareholders to hold the course; shares currently trade well above the $120 offer. The bidding process will take awhile, and if shares fall, it’s easier for bidders to justify a lower final offer.

Here’s a look at the potential suitors, assuming the bankers are telling the truth, of course.

Obvious
It’s not surprising to see Amgen, Inc. (NASDAQ:AMGN) in the mix of bidders given its initial interest. With its oncology focus, Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) would be a nice fit. At $10 billion, buying Onyx would be the largest purchase Amgen has made since it bought Immunex more than a decade ago. With more than $20 million in the bank, though, Amgen can certainly afford it.

Big pharma
The two big pharma being mentioned by the insiders, Pfizer Inc. (NYSE:PFE) and Bristol Myers Squibb Co. (NYSE:BMY), are the two obvious choices given their focus on oncology.

Bristol Myers Squibb Co. (NYSE:BMY) has build much of its medicine bag and pipeline through acquisitions in a strategy it calls “string of pearls,” so acquiring Onyx would just be adding another pearl — albeit a rather large one. A knock on a big pharma company buying Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) is that it would have to work with Onyx’s partner, Bayer, co-marketing their cancer drug Nexavar, but that shouldn’t phase Bristol Myers Squibb Co. (NYSE:BMY) given that it’s worked with Sanofi SA (ADR) (NYSE:SNY) selling Plavix and more recently hocking diabetes drugs with AstraZeneca plc (ADR) (NYSE:AZN).

Onyx would be an interesting fit with Pfizer. They’re competitors of sorts since Pfizer Inc. (NYSE:PFE)’s Sutent works in basically the same way as Onyx’s Nexavar. But the companies have found separate niches with Sutent getting most of its sales from kidney cancer and Nexavar focused on liver cancer, even though it’s also approved for kidney cancer. Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) and Pfizer Inc. (NYSE:PFE) also have a partnership for another cancer drug in development, palbociclib, so buying Onyx would save Pfizer the having to pay the royalty if the drug is approved.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

The 10 Most Peaceful Countries in the World

5 Big Reasons Communism Failed

The 15 Most Famous Carl Icahn Quotes

10 Scary Animals that are Actually Harmless

The 8 Most Famous Singer-Actors in Entertainment

The 10 Longest Wars of All Time

The 13 Worst Looking Foods that Taste Great

The 6 Most Gruesome Injuries Suffered During a Sports Match

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!